Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
London, UK – 1 Sept 2015: Smoking prevalence has stayed the same but the proportion with no intention of quitting has risen in the last seven years, according to results from the latest EUROASPIRE surveys presented for the first time today at ESC Congress 2015 by Professor Kornelia Kotseva, chair of the EUROASPIRE Steering Committee and senior clinical research fellow at Imperial College London, UK.1
EMBARGO : 1 September 2015 at 11:00 BST
EUROASPIRE is a series of cross sectional surveys of the practice of preventive cardiology in patients with coronary heart disease (CHD) and people at high risk of developing cardiovascular disease (CVD) across Europe. Four EUROASPIRE surveys have been conducted under the ESC’s EORP initiative.2 EUROASPIRE III, conducted in 2006 to 2008, included for the first time people at high risk of developing CVD in general practice from 12 countries. The primary care arm of EUROASPIRE IV was carried out in 2014 to 2015 in 14 countries.The current study was a time trend analysis of lifestyle, risk factor and therapeutic management in people at high risk of developing cardiovascular disease between the EUROASPIRE III and IV surveys in general practice. It was conducted in the five countries (Bulgaria, Croatia, Poland, Romania and the UK) that participated in both surveys. A total of 5 890 consecutive patients were included of whom 3 827 were interviewed across the two surveys.“We wanted to see whether there had been any change in lifestyles or risk factors between the two surveys and whether the practice of preventive cardiology in patients at high risk of developing CVD had improved over time,” said Professor Kotseva.In each general practice, consecutive patients under the age of 80 years, with no history of coronary or other atherosclerotic disease, who had been prescribed one or more of the following medications: (i) anti-hypertensive and/or (ii) lipid lowering and/or (iii) anti-diabetes treatments (diet and/or oral hypoglycaemics and/or insulin) were retrospectively identified and invited to an interview and examination. Study interviews took place ≥6 months and ≤3 years after the recruitment interview. The primary endpoints were the proportions of patients achieving targets for CVD prevention in the 2012 European societies’ guidelines.3The analysis shows that smoking prevalence stayed the same (17% in both surveys; p=0.90) and remained highest in patients <50 years. The proportion of smokers with no intention of quitting increased from 23% to 34% (p=0.004). Professor Kotseva said: “The highest levels of smoking are still in the youngest patients who have the most to gain from quitting. But the use of pharmacotherapy for smoking cessation remained very low over the seven years so more emphasis is needed in this area.”There was no change across the two surveys in the prevalence of overweight (82% and 82%; p=0.85), obesity (44% and 43%; p=0.88) or central obesity (59% and 62%; p=0.05), or in levels of physical activity. Less than one in five patients in both surveys reported having vigorous physical activity outside work for ≥ 20 minutes at least three times a week (16% and 19%; p=0.68).Therapeutic control of blood pressure in patients using blood pressure lowering medication slightly improved but not significantly (28% and 35%; p=0.12), with 65% of patients above the recommended target (systolic <140 mmHg and/or diastolic <90 mmHg; <140/80 mmHg in patients with diabetes) in EUROASPIRE IV.The proportion of patients on lipid-lowering medication who met the LDL cholesterol target (<2.5 mmol/L) increased insignificantly from 29% to 37% (p=0.38). However, 63% of patients still did not reach the target. Glycaemic control in patients with diabetes remained unchanged (62% and 60%; p=0.75), with 40% of patients not achieving the target of HbA1c <7% in EUROASPIRE IV.“Lifestyle trends are not moving in the right direction,” said Professor Kotseva. “The prevalence of smoking, obesity and central obesity has not changed over the two surveys with more than four in five people at high risk of developing cardiovascular disease being overweight or obese. The therapeutic control of blood pressure and lipids has not improved significantly and the vast majority of patients do not reach the targets defined in the guidelines.”She concluded “Our analysis highlights the pressing need for modern preventive cardiology programmes integrating lifestyle and medical risk factor management, adapted to the medical and cultural settings in each country. Health care systems that invest in prevention are urgently needed.”ENDS
1Professor Kotseva will give the presentation ‘Clinical reality of primary prevention in people at high cardiovascular risk in Europe: a comparison of EUROASPIRE III and IV surveys in general practice’ at 11:00 during:• The session ‘Registry III – Prevention’ on Tuesday 1 September at 11:00 in Hyde Park (The Hub) 2About EORP: EURObservational Research Programme (EORP) is the large ESC registry programme. EORP aims at providing a better understanding of medical practice in Europe through the collection of observational data and at evaluating the implementation of ESC guidelines.3European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Heart Journal. 2012;33:1635–1701.
Principal results of EUROASPIRE IV presented for the first time at ESC CongressProfessor Guy De Backer will present the principal results of the EUROASPIRE IV survey for the first time during the Symposium ‘How are we managing cardiovascular risk in the primary care environment? EUROASPIRE IV survey’, held on Sunday 30 August at 11:00 in the Bratislava room, Village 2
SOURCES OF FUNDING: The EUROASPIRE IV survey was carried out under the auspices of the European Society of Cardiology, EURObservational Research Programme. The survey was supported through unrestricted research grants to the European Society of Cardiology from Amgen, AstraZeneca, Bristol-Myers Squibb and AstraZeneca, F. Hoffman-La Roche, GlaxoSmithKline, and Merck Sharp & Dohme. The sponsors of the EUROASPIRE surveys had no role in the design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript.
DISCLOSURES: Professor Kotseva had research grant support from the European Society of Cardiology for the EUROASPIRE IV survey.
ESC Press OfficeFor background information or assistance, please contact the ESC Press Office.For independent comment on site or interviews, please contact the ESC spokesperson coordinator: +44 7785 467 947
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at email@example.com.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
© 2017 European Society of Cardiology. All rights reserved